SHIRLEY, N.Y.—Today chemical company BOC Sciences announced that the company has established a medicinal chemistry branch, which is specially designed to support scientists’ needs arising from drug discovery efforts. The branch is intended to cover nearly the whole process of a drug discovery project, from lead discovery all the way to formulation issues.
“In this field, chemists who focus on drug R&D are also concerned with the isolation of medicinal agents found in plants, as well as the creation of new synthetic drug compounds. Our chemists work in a team full of pharmacologists, theoretical chemists, biologists, toxicologists, microbiologists, and biopharmacists, all coming from different background,” said Barron Jones, marketing chief of BOC Sciences.
“Together, this team uses sophisticated analytical techniques to synthesize and test new drug products and at the same time, to develop the most cost-effective and environmentally friendly means for mass production," added Jones. "Considering all the possible challenges that could arise during the drug development process, our management decided to designate a special branch to be responsible for all these tasks.”
Medicinal chemistry is an integrated discipline which links many scientific fields in new drug research and development. In this process medicinal chemists apply their chemistry training to the process of synthesizing new pharmaceuticals. Different procedures are involved — in most cases, it begins with the synthesis of potential drugs and is followed by studies investigating their interactions with biological targets so as to understand the medicinal effects of the drug, its metabolism and side-effects.
“Medicinal chemistry deals with the design, optimization and development of chemical compounds for use as drugs,” notes BOC Sciences’ website. “It is inherently a multidisciplinary topic, i.e., beginning with the synthesis of potential drugs followed by studies investigating their interactions with biological targets to understand the medicinal effects of the drug, its metabolism and side-effects.”
BOC Sciences currently has screening libraries, lead discovery and optimization, and computer-aided drug discovery (CADD) services available in their medicinal chemistry branch.
“We offer integrated approaches from hit discovery to preclinical candidate and maximize efficiency by accessing the widest range of services,” the website continues. “Our medicinal chemistry team is world-class, with many scientists bringing a wealth of experience from previous employment in the pharmaceutical and biotechnology industries.”
For hit screening, a series of unique and high-purity compound libraries are specially designed, including HTS libraries, fragment libraries, activity based libraries and custom libraries. A comprehensive service range covering hit identification, hit to lead, lead optimization and chemical resynthesis is offered as well. During these processes, the application of computer-aided drug discovery could help advance drug discovery projects, including compound docking, virtual screening, activity prediction, QSAR prediction and physicochemical prediction using theses simulation techniques and software.
“Our project management team has a lot of experience in all aspects of new drug projects. Much experience with coordinating ADME, crystallography, and assay services, and we offer solutions for maintaining a database for all project data,” states the website. “They are adept at planning, organizing, managing, and assigning resources so as to achieve a specific goal.”